Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
Oslo, Norway, 8 January 2018: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Michael Bogenstaetter has been …